A prospective, randomized, open-label, parallel trial comparing the efficacy of α-blocker or 5α-reductase inhibitor withdrawal to continued combination therapy on the maintenance of lower urinary tract symptoms in men with benign prostatic hyperplasia.
Kwang-Suk LeeJeong Woo YooDae Ho KimSoyoung JeonJuyeon YangByung Ha ChungKyo Chul KooPublished in: The Prostate (2023)
In patients with BPH/LUTS who are reluctant to continue combination therapy, AB or 5ARI withdrawal may be offered in men with improvement in IPSS-T by at least seven points and reduction in PV by at least 20%.